Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-time PCR kits and thalassemia genoarray diagnostic kits; hearing loss susceptibility genoarray diagnostic kits; COVID-19 real-time PCR kits; and devices/instruments, including automated nucleic acid extraction, automatic medical PCR analysis, flow-through hybridization, auto DNA extraction, and fluorescent quantitative detection systems, as well as after-sales technical service support. Its products are used in the fields of national screening, clinical, and research purposes. The company operates in the Asia Pacific, the South East Asia, the Middle East, Europe, Africa, and South America. Guangdong Hybribio Biotech Co.,Ltd. was founded in 2003 and is based in Sheung Wan, Hong Kong.

Guangdong Hybribio Biotech Co.,Ltd.

凯普生物 is focused on the research, development, production, and sales of nucleic acid molecular diagnostic products, including molecular diagnostic reagents and related instruments. It also provides related services.

3006

CN:HYBRIBIO

凯普生物

Last Close

6.54

25/11 07:04

Market Cap

3.08B

Beta: -

Volume Today

28.42M

Avg: -